In last week’s Ausbiz interview, I explored investor sentiment surrounding the latest GLP-1 medications, specifically on Ozempic and its implications for companies like CSL (ASX: CSL) and ResMed (ASX: RMD). While the drop in CSL’s share value suggests market concerns about competing Ozempic-style drugs, I argue that these anxieties may be unfounded. My perspective rests on the belief that such medications might not be as transformative in addressing the weight of the U.S. population as investors might anticipate and the affordability surrounding it. Watch the full interview here. Ausbiz – The market’s ‘weighty’ overreaction…

The Montgomery Fund and the Montgomery [Private] Fund own shares in CSL. This blog was prepared 10 November 2023 with the information we have today, and our view may change. It does not constitute formal advice or professional investment advice. If you wish to trade in CSL, you should seek financial advice.